Semliki forest virus: A viral vector with multiple applications;Semliki forest virus: Un vector viral con múltiples aplicaciones

Colombia Medica

Volumn 38, Issue 2, 2007, Pages 159-169

  Henao, Luis Felipe ^a   Cortés, Fabrián ^a   Navas, María Cristina ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Gene expression; Semliki forest virus; Transduction genetic

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; VIRUS PROTEIN; VIRUS VECTOR;

ARTICLE; CANCER GENE THERAPY; CELLULAR IMMUNITY; CYTOTOXICITY; EXPRESSION VECTOR; GENETIC TRANSCRIPTION; HUMAN; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MAMMAL CELL; NERVOUS SYSTEM TUMOR; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SEMLIKI FOREST ALPHAVIRUS; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS DETECTION; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

EID: 34347396451     PISSN: 16579534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Roks AJ, Pinto YM, Paul M, Pries F, Stula M, Eschenhagen T, et al. Vectors based on Semliki Forest virus for rapid and efficient gene transfer into non-endothelial cardiovascular cells: Comparison to adenovirus. Cardiovasc Res 1997; 35: 498-504.
2. Fotaki ME, Pink JR, Mous J. Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer. Gene Ther 1997; 4: 901-908.
3. Paterna JC, Moccetti T, Mura A, Feldon J, Büeler H. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther 2000; 7: 1304-1311.
4. Mountain A. Gene therapy: The first decade. Trends Biotechnol 2000; 18: 119-128.
5. Wu N, Ataai MM. Production of viral vectors for gene therapy applications. Curr Opin Biotechnol 2000; 11: 205-208.
6. Schlesinger S. Alphavirus expression systems -promises and problems. ASM News 1999; 65: 688-695.
7. Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biol Technology 1991; 9: 1356-1361.
8. Liljeström P, Garoff H. SFV expression systems. Technical manual. Huddinge: Novum Research Center; 1993. 31 pp.
9. Wahlberg JM, Bron R, Wilschut J, Garoff H. Membrane fusion of Semliki Forest virus involves homotrimers of the fusion protein. J Virol 1992; 66: 7309-7318.
10. Lu YE, Kielian M. Semliki forest virus budding: Assay, mechanisms, and cholesterol requirement. J Virol 2000; 74: 7708-7719.
11. Kujala P, Ikaheimonen A, Ehsani N, Vihinen H, Auvinen P, Kaariainen L. Biogenesis of the Semliki Forest virus RNA replication complex. J Virol 2001; 75: 3873-3884.
12. Berglund P, Sjoberg M, Garoff H, Atkins GJ, Sheahan BJ, Liljeström P. Semliki Forest virus expression system: Production of conditionally infectious recombinant particles. Biol Technology 1993; 11: 916-920.
13. Smerdou C, Liljeström P. Two-Helper RNA System for Production of Recombinant Semliki Forest Virus Particles. J Virol 1999; 73: 1092-1098.
14. Tamberg N, Lulla V, Fragkoudis R, Lulla A, Fazakerley JK, Merits A. Insertion of EGFP into the replicase gene of Semliki Forest virus results in a novel, genetically stable marker virus. J Gen Virol 2007; 88 (Pt 4): 1225-1230.
15. Lundstrom K, Schweitzer C, Richards JG, Ehrengruber MU, Jenck F, Mülhardt C. Semliki Forest virus vectors for in vitro and in vivo applications. Gene Ther Mol Biol 1999; 4: 23-431.
16. Lundstrom K, Abenavoli A, Malgaroli A, Ehrengruber MU. Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression. Mol Ther 2003; 7: 202-209.
17. Lundstrom K, Rotmann D, Hermann D, Schneider EM, Ehrengruber MU. Novel mutant Semliki Forest virus vectors: Gene expression and localization studies in neuronal cells. Histochem Cell Biol 2001; 115: 83-91.
18. Perri S, Driver DA, Gardner JP, Sherrill S, Belli BA, Dubensky TW Jr, et al. Replicon vectors derived from Sindbis virus and Semliki forest virus that establish persistent replication in host cells. J Virol 2000; 74: 9802-9807.
19. DiCiommo DP, Bremner R. Rapid, high level protein production using DNA-based Semliki Forest virus vectors. J Biol Chem 1998; 273: 18060-18066.
20. Colmenero P, Berglund P, Kambayashi T, Biberfeld P, Liljeström P, Jondal M. Recombinant Semliki Forest virus vaccine vectors: The route of injection determines the localization of vector RNA and subsequent T cell response. Gene Ther 2001; 8: 1307-1314.
21. Lundstrom K, Michel A, Blasey H, Bernard AR, Hovius R, Vogel H, et al. Expression of ligand-gated ion channels with the Semliki Forest virus expression system. J Recept Signal Transduct Res 1997; 17: 115-126.
22. Torresi J, Meanger J, Lambert P, Li F, Locarnini SA, Anderson DA. High level expression of the capsid protein of hepatitis E virus in diverse eukaryotic cells using the Semliki Forest virus replicon. J Virol Methods 1997; 69: 81-91.
23. Kehm E, Goksu MA, Knopf CW. Expression analysis of recombinant herpes simplex virus type 1 DNase. Virus Genes 1998; 17: 129-138.
24. Nilsson M, von Bonsdorff CH, Weclewicz K, Cohen J, Svensson L. Assembly of viroplasm and virus-like particles of rotavirus by a Semliki Forest virus replicon. Virology 1998; 242: 255-265.
25. Giraud A, Ataman-Onal Y, Battail N, Piga N, Brand D, Mandrand B, et al. Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. J Virol Methods 1999; 79: 75-84.
26. Greive SJ, Webb RI, Mackenzie JM, Gowans EJ. Expression of the hepatitis C virus structural proteins in mammalian cells induces morphology similar to that in natural infection. J Viral Hepat 2002; 9: 9-17.
27. Henao LF, Yepes JO, Álvarez CM, Bálcazar N, Navas MC. Expresión de la proteína verde fluorescente y proteína Core del Virus de la hepatitis C en la línea de hepatoma HepG2 mediante el sistema de expresión del Semliki Forest Virus. Acta Biol 2004; 25: 23-29.
28. Yepes JO, Gunturiz ML, Henao LF, Navas MC, Balcázar N, Gómez LA. Presentación diferencial de ARN mensajeros e identificación del gen selenocisteína liasa en células de carcinoma hepatocelular con expresión transitoria de la proteína core del virus de la hepatitis C. Biomedica 2006; 26: 194-205.
29. Ehrengruber MU, Lundstrom K, Schweitzer C, Heuss C, Schlesinger S, Gahwiler BH. Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures. Proc Natl Acad Sci USA 1999; 96: 7041-7046.
30. Murphy AM, Morris-Downes MM, Sheahan BJ, Atkins GJ. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Ther 2000; 7: 1477-1482.
31. Hardy PA, Mazzini MJ, Schweitzer C, Lundstrom K, Glode LM. Recombinant Semliki forest virus infects and kills human prostate cancer cell lines and prostatic duct epithelial cells ex vivo. Int J Mol Med 2000; 5: 241-245.
32. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med 1999; 5: 823-827.
33. Colmenero P, Chen M, Castaños-Vélez E, Liljestrom P, Jondal M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int J Cancer 2002; 98: 554-560.
34. Chikkanna-Gowda CP, Sheahan BJ, Fleeton MN, Atkins GJ. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther 2005; 12: 1253-1263.
35. Rodríguez-Madoz JR, Prieto J, Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 2005; 12: 153-163.
36. Yamanaka R, Tsuchiya N, Yajima N, Honma J, Hasegawa H, Tanaka R, et al. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulssed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 2003; 99: 746-753.
37. Daemen T, Riezebos-Brilman A, Regts J, Dontje B, van der Zee A, Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 2004; 9: 733-742.
38. Kim TG, Kim CH, Won EH, Bae SM, Ahn WS, Park JB, et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology 2004; 112: 117-125.
39. Yamanaka R. Alphavirus vectors for cancer gene therapy. Int J Oncol 2004; 24: 919-923.
40. Loot AE, Henning RH, Deelman LE, Tio RA, Schoen P, Wilschut JC, et al. Semliki Forest virus is an efficient and selective vector for gene delivery in infarcted rat heart. J Mol Cell Cardiol 2004; 37: 137-142.
41. Vaha-Koskela MJ, Kuusinen TI, Holmlund-Hampf JC, Furu PT, Heikkila JE, Hinkkanen AE. Semliki Forest virus vectors expressing transforming growth factor beta inhibit experimental autoimmune encephalomyelitis in Balb/c mice. Biochem Biophys Res Commun 2007; 355: 776-781.
42. Wahlfors JJ, Zullo SA, Loimas S, Nelson DM, Morgan RA. Evaluation of recombinant alphaviruses as vectors in gene therapy. Gene Ther 2000; 7: 472-480.
43. Zhou X, Berglund P, Zhao H, Liljeström P, Jondal M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci USA 1995; 92: 3009-3013.
44. Malone JG, Bergland PJ, Liljeström P, Rhodes GH, Malone RW. Mucosal immune responses associated with polynucleotide vaccination. Behring Inst Mitt 1997; 98: 63-72.
45. Berglund P, Fleeton MN, Smerdou C, Liljeström P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999; 17: 497-507.
46. Vignuzzi M, Gerbaud S, van der Werf S, Escriou N. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J Gen Virol 2001; 82: 1737-1747.
47. Fleeton MN, Liljeström P, Sheahan BJ, Atkins GJ. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol 2000; 81: 749-758.
48. Colombage G, Hall R, Pavy M, Lobigs M. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 1998; 250: 151-163.
49. Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, Liljeström P. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type envelope protein and challenged with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 1997; 13: 1487-1495.
50. Notka F, Stahl-Hennig C, Dittmer U, Wolf H, Wagner R. Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies. Vaccine 1999; 18: 291-301.
51. Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, Larke N, Liljeström P, et al. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 2003; 84: 361-368.
52. Sundback M, Douagi I, Dayaraj C, Forsell MN, Nordstrom EK, McInerney GM, et al. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles. Virology 2005; 341: 190-202.
53. Negri DR, Baroncelli S, Catone S, Comini A, Michelini Z, Maggiorella MT, et al. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J Gen Virol 2004; 85: 1191-1201.
54. Brinster C, Inchauspe G. DNA vaccines for hepatitis C virus. Intervirology 2002; 44: 143-153.
55. Brinster C, Chen M, Boucreux D, Paranhos-Baccala G, Liljeström P, Lemmonier F, et al. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 2002; 83: 369-381.
56. Frelin L, Ahlen G, Alheim M, Weiland O, Barnfield C, Liljeström P, et al. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus non-structural 3/4A gene. Gene Ther 2004; 11: 522-533.
57. Rollier C, Verschoor EJ, Paranhos-Baccala G, Drexhage JA, Verstrepen BE, Berland JL, et al. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J Infect Dis 2005; 192: 920-929.
58. Vidalin O, Fournillier A, Renard N, Chen M, Depla E, Boucreux D, et al. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki Forest virus-derived particles for the induction of immune responses against hepatitis C virus Core and E2 antigens. Virology 2000; 276: 259-270.
59. Morris-Downes MM, Phenix KV, Smyth J, Sheahan BJ, Lileqvist S, Mooney DA, et al. Semliki Forest virus-based vaccines: Persistence, distribution and pathological analysis in two animal systems. Vaccine 2001; 19: 1978-1988.
60. Lundstrom K. Semliki Forest virus vectors for gene therapy. Expert Opin Biol Ther 2003; 3: 771-777.
61. Krasemann S, Jürgens T, Bodemer W. Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy. J Biotechnol 1999; 73: 119-129.
62. Keogh B, Atkins GJ, Mills KH, Sheahan BJ. Avirulent Semliki Forest virus replication and pathology in the central nervous system is enhanced in IL-12-defective and reduced in IL-4-defective mice: A role for Th1 cells in the protective immunity. J Neuroimmunol 2002; 125: 15-22.
63. Ivanova L, Schlesinger S, Olivo PD. Regulated expression of a Sindbis virus replicon by herpesvirus promoters. J Virol 1999; 73: 1998-2005.